Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

D.S. Krupashankar, Sunil Dogra, Mahendra Kura, Abir Saraswat, Leelavathy Budamakuntla, T.K. Sumathy, Radha Shah, M.G. Gopal, T. Narayana Rao, C.R. Srinivas, Ramesh Bhat, Narendra Shetty, G. Manmohan, Kotla Sai Krishna, Dalavoi Padmaja, Dasiga Venkata Subrahmanya Pratap, Vijay Garg, Sandesh Gupta, Neeraj Pandey, Uday Khopkar, Enrique Montero, M.S. Ramakrishnan, Pradip Nair, Prasanna C. Ganapathi

Open source

DOI: 10.1016/j.jaad.2014.01.897
Published: 2014-09
Container: Journal of the American Academy of Dermatology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jaad.2014.01.897,
  title = {Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study},
  author = {D.S. Krupashankar and Sunil Dogra and Mahendra Kura and Abir Saraswat and Leelavathy Budamakuntla and T.K. Sumathy and Radha Shah and M.G. Gopal and T. Narayana Rao and C.R. Srinivas and Ramesh Bhat and Narendra Shetty and G. Manmohan and Kotla Sai Krishna and Dalavoi Padmaja and Dasiga Venkata Subrahmanya Pratap and Vijay Garg and Sandesh Gupta and Neeraj Pandey and Uday Khopkar and Enrique Montero and M.S. Ramakrishnan and Pradip Nair and Prasanna C. Ganapathi},
  year = {2014},
  journal = {Journal of the American Academy of Dermatology},
  doi = {10.1016/j.jaad.2014.01.897},
  url = {https://doi.org/10.1016/j.jaad.2014.01.897}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study
AU  - D.S. Krupashankar
AU  - Sunil Dogra
AU  - Mahendra Kura
AU  - Abir Saraswat
AU  - Leelavathy Budamakuntla
AU  - T.K. Sumathy
AU  - Radha Shah
AU  - M.G. Gopal
AU  - T. Narayana Rao
AU  - C.R. Srinivas
AU  - Ramesh Bhat
AU  - Narendra Shetty
AU  - G. Manmohan
AU  - Kotla Sai Krishna
AU  - Dalavoi Padmaja
AU  - Dasiga Venkata Subrahmanya Pratap
AU  - Vijay Garg
AU  - Sandesh Gupta
AU  - Neeraj Pandey
AU  - Uday Khopkar
AU  - Enrique Montero
AU  - M.S. Ramakrishnan
AU  - Pradip Nair
AU  - Prasanna C. Ganapathi
PY  - 2014
JO  - Journal of the American Academy of Dermatology
DO  - 10.1016/j.jaad.2014.01.897
UR  - https://doi.org/10.1016/j.jaad.2014.01.897
ER  -

APA

Krupashankar, D., Dogra, S., Kura, M., Saraswat, A., Budamakuntla, L., Sumathy, T., Shah, R., Gopal, M., Rao, T. N., Srinivas, C., Bhat, R., Shetty, N., Manmohan, G., Krishna, K. S., Padmaja, D., Pratap, D. V. S., Garg, V., Gupta, S., Pandey, N., Khopkar, U., Montero, E., Ramakrishnan, M., Nair, P., & Ganapathi, P. C. (2014). Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2014.01.897

Source records

crossref · retrieved 2026-09-27T09:38:26.749Z